亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

2015 ESC Guidelines for the diagnosis and management of pericardial diseases

医学 卫生专业人员 药方 模棱两可 医疗保健 公共关系 医疗急救 护理部 法学 哲学 语言学 政治学
作者
Yehuda Adler,Philippe Charron,Massimo Imazio,Luigi Paolo Badano,Gonzalo Barón‐Esquivias,Jan G. Bogaert,Antonio Luca Brucato,Pascal Guéret,Karin Klingel,Christos D Lionis,Bernhard Maisch,Bongani M. Mayosi,Alain Pavie,Arsen D. Ristić,Manel Sabaté,Petar Seferovic,Karl B Swedberg,Witold Zbyszek Tomkowski,ESC Scientific Document Group,Stephan S. Achenbach
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:36 (42): 2921-2964 被引量:3083
标识
DOI:10.1093/eurheartj/ehv318
摘要

adenosine deaminase acute myocardial infarction anti-nuclear antibody basic fibroblast growth factor creatine kinase cardiac magnetic resonance cytomegalovirus Child–Pugh C-reactive protein computed tomography Epstein–Barr virus electrocardiogram erythrocyte sedimentation rate end-stage renal disease fluorodeoxyglucose familial Mediterranean fever granulocyte-macrophage colony-stimulating factor human herpesvirus human immunodeficiency virus hazard ratio interleukin intravenous immunoglobulins late contrast-enhanced non-steroidal anti-inflammatory drugs odds ratio pulmonary arterial hypertension post-cardiac injury syndromes polymerase chain reaction positron emission tomography post-pericardiotomy syndrome randomized controlled trial species steady-state free-precession short-tau inversion-recovery tuberculosis tumour necrosis factor tumour necrosis factor receptor-associated periodic syndrome thyroid stimulating hormone treatment unstimulated interferon-gamma vascular endothelial growth factor Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC Web Site (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 and 2. The experts of the writing and reviewing panels provided declarations of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of interest that arise during the writing period must be notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry. The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement all guidelines, condensed pocket guidelines versions, summary slides, booklets with essential messages, summary cards for non-specialists, and an electronic version for digital applications (smartphones, etc.) are produced. These versions are abridged and thus, if needed, one should always refer to the full text version, which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, translate and implement the ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations. Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription. Classes of recommendations Levels of evidence The pericardium (from the Greek περί, ‘around’ and κάρδιον, ‘heart’) is a double-walled sac containing the heart and the roots of the great vessels. The pericardial sac has two layers, a serous visceral layer (also known as epicardium when it comes into contact with the myocardium) and a fibrous parietal layer. It encloses the pericardial cavity, which contains pericardial fluid. The pericardium fixes the heart to the mediastinum, gives protection against infection and provides lubrication for the heart. Pericardial diseases may be either isolated disease or part of a systemic disease.1–5 The pericardial syndromes that are in clinical practice and pericardial cardiac and pericardial medical for pericardial diseases are has been for a pericardial Pericardial diseases are in clinical practice and new data have been published the publication of the ESC Guidelines on pericardial diagnostic strategies have been for the of patients with and pericardial and the of patients to be as well as when and diagnostic are to be diagnostic criteria have been for acute and in clinical for pericardial diseases has an essential for a and comprehensive diagnostic the Society of and the European of have provided recommendation in recent The and of pericardial diseases to be but new data the of and new forms to diseases have been in The data have and are and including recommendations for patients during have in with the randomized clinical has been as a to be to anti-inflammatory in patients with a of or in order to the to and therapeutic without a and have been to patient therapeutic have available for including intravenous immunoglobulins and has been as a to medical in patients with The and have the and in patients with acute and for the of pericardial cardiac magnetic resonance may forms of a trial of medical anti-inflammatory that may the for new data have available and a new version of guidelines has for clinical practice. in the field of pericardial diseases are a number of randomized controlled the number of level A are the of pericardial are from is the most disease of the pericardium in clinical practice. The of acute has been as in an is responsible for of all and of for from a a rate of for acute of These data were to patients and may account for only a of as patients with are not to years were at for in the with the with the of all The of by an in The rate for acute was and was with and or However, this is a on of patients after a of acute A for pericardial diseases is to and The is and on the patient and clinical developed are the most of tuberculosis is the most of pericardial diseases in the and developing where is this is with human immunodeficiency virus in of pericardial The pericardium may be by all of including and granulocyte-macrophage human necrosis Pericardial syndromes clinical of pericardial diseases with and that can be in The pericardial syndromes pericardial cardiac and Pericardial and cardiac may without and be in to with and myocardial to in the as is an pericardial syndrome with or without pericardial The clinical can be made with two of the criteria of and by and pericardial of or best with the of the the electrocardiogram changes to of new or in the acute and pericardial to of and may be according to the or systemic disease and of systemic infection as fever and or systemic disease or and diagnostic criteria for text for cardiac magnetic computed but a of time has not been has been as a of acute However, changes in the of the the parietal pericardium is changes have been in to of The of changes with acute is from one patient to and is by acute syndromes with and of of C-reactive protein and erythrocyte sedimentation rate as well as of the is a and in patients with acute and may be for the of the disease and of with may with an of of myocardial injury creatine kinase A is in patients with acute an ratio only with pericardial the of of involvement may be found in patients with for of acute creatine C-reactive of of recommendations. It is not to for the in all in with a of because of the with the of and the of diagnostic final as well as in the of acute have been as with an of during and The with after fever without a acute evidence of pericardial cardiac and to to non-steroidal anti-inflammatory drugs should also be these are on expert and including with and this a for acute is Web Any clinical that may an a systemic or with at one of or and an the other patients without these can be as with and after 1 to the to for the management of acute of of recommendations. 1 and of patients with a other appropriate to the is and the of should be The recommendation is to of and of for patients not involved in are recommended to to only after have and diagnostic and have been A of the of the has been according to expert this only to a period may be for or are of for acute anti-inflammatory drugs have been anti-inflammatory for acute C-reactive non-steroidal anti-inflammatory should be for and is and but for should be is on of or The of should be on the of the patient or the of diseases other when is needed as and of is recommended at to the to medical and of is not but may be to of and should be as a in patients with and of or because of the of the of the disease and in this are with to or should be recommended of or The should be of and of should be for the treatment of acute C-reactive non-steroidal anti-inflammatory of of recommendations. to patients with acute with or have a in patients with acute and is in patients with a as or may in of patients with acute and is also in patients with a The of developing can be as for and for and and for with and of patients with acute are not with either or may the The has been for with without a after the acute The for pericardial disease The Task Force that the should be for for with for is the of anti-inflammatory and its and for is with a of acute a of or and evidence of of of is established according to the criteria as for acute computed tomography and/or may to support the in or pericardial evidence of and of the The rate after an of from to and may to after a in patients not with if with developed the is not in most and it is to be A of is treatment of the of to of when have been on pericardial and a is should be at the in patients with an or the of Web Web is recommended on of anti-inflammatory without a and daily if is or daily if it is for Web in order to the to medical and anti-inflammatory for Web Tables and should be for and for may be of to and may be but should be at to to and as not these in order to of at to should be if and be and should be to patients with systemic post-pericardiotomy or recent or when the is or or or disease appropriate of and are their should be A critical for is a of or this as as at of are of should be made not to the or to and After a should be with a of at a time is in the most are after of each should be only if are and is The Task Force not as a for in patients with the virus is not a of The should be according to are and or of the may or an of to systemic to may be of but this patients of or do not to anti-inflammatory drugs have been including but also and a but data are drugs necrosis factor have been only might be and with the to the individual patient and is a to the disease for a and are during the acute may after as and may be in of not to after careful assessment of the and consultation by including and/or in the of a It is also to the patient and the clinical to drugs and the to during the a may be but only after a thorough trial of medical and with of the patient to a with in this The in acute also to for the management of C-reactive intravenous non-steroidal anti-inflammatory of of recommendations. are in is and at the of the has been in these and the is that after a of acute it is to patients their the of the disease and its The are to the and not to the number of treatment should take into account this outcome to However, quality of can be in patients with or and for acute and text for and and forms may be in clinical with known or myocardial involvement should be to as with pericardial involvement should be to as according to Task Force The is with other of and pericardial the of of myocardial clinical data on the of that are the most in developed other are in developing can pericardial and myocardial or and/or are involved in with diseases and or of are other cardiac and are by systemic of infection or are by or are with an acute acute or The of and of has the number of The of with myocardial or can be established if patients with criteria for acute of myocardial injury or without developed or of in or The a syndrome with myocardial which the of and in clinical the other evidence of or of in patients with myocardial and clinical criteria for acute with pericardial involvement of the of according to the and Pericardial position However, the of patients with myocardial involvement in with or and of heart not of with to clinical and factor is recommended in order to acute is recommended for the of myocardial involvement and to myocardial necrosis in the of this has clinical and therapeutic is recommended for and of patients with myocardial involvement and diagnosis, with acute the of management is to that recommended for anti-inflammatory or or are to are as a in of or of the of as with because in of have been shown to be and may However, the application of these from to may be are data to the of which is a treatment for acute and the of for most recommendations are and of is recommended in all patients with cardiac have been in after and also in without in isolated to is when is evidence of disease in or after in the or of myocardial involvement to of for at from the of the according to expert and recommendations for in involvement in has a and have to heart or in patients with for the and management of with of of recommendations. The pericardial sac contains of pericardial as a that as a between the pericardial Any process an with the of of pericardial of of pericardial may be to a in systemic as a of heart or pulmonary hypertension Pericardial may be according to its or when or impact cardiac or from in by its on a assessment as or assessment has also to be in the of and during in the of the have been published on the of to pericardial of is provided for for and only for a with to are to in should be only if the patient is and C-reactive protein is for and should be to all patients are recommended to in all years and in treatment with is at a of or of pericardial A of patients with pericardial are and pericardial an and on or for other to these in developed to other and diseases is the in developing where is the of with pericardial the of or from to on the published The clinical of pericardial according to the of pericardial pericardial is as after or the is and of may an in and cardiac the other a of pericardial the of a in to a in pericardial and on to and/or to may and and and the of the pericardial on or and is a that may be with either or systemic may be in patients without with at and heart on cardiac in of to Pericardial are can be in patients with The of pericardial is by which also assessment of the pericardial and its the diagnostic for the of pericardial diseases because of its and and a larger field of the of pericardial and pericardial and as well as for the of pericardial cardiac magnetic C-reactive computed of of recommendations. a pericardial is the is to its the of cardiac and diseases or systemic Pericardial is with known or medical to of are the clinical management should be that of without is with a of a ratio a without cardiac and is with a ratio A evaluation for of pericardial is in for the management of pericardial of of recommendations. criteria as for with are data on non-steroidal anti-inflammatory drugs and of are a trial of and/or and/or may be of pericardial should be at the as as of the is with a known disease and the essential treatment is that of the pericardial is with management should that of a pericardial without evidence of or when anti-inflammatory drugs are not of the should be with pericardial of to may be in order to of pericardial and of evidence to support this is on and expert A for pericardial and are medical to an isolated the of and are not may be for the of but are also and or options pericardial should be or is for the of pericardial non-steroidal anti-inflammatory of of recommendations. The of pericardial is to the The of the is with the as to are for as and pericardial and have an with a of if the is to with these a published has shown that with pericardial the may be in and have a of to cardiac not to and with of of the may have an of according to in has a of the is to the and not the number of The of pericardial is on the evaluation of and the of the as well as as A is has a and not to may and may cardiac in to of an appropriate for may be an a an may be A is also the or of the on pericardial in the are in the on post-cardiac injury syndromes is a or of the heart to the pericardial of or as a of of the heart or in a patient with cardiac heart with and an cardiac on with A diagnostic is as an in arterial of during is to in cardiac when the of cardiac and any in the of one of the heart the changes in the other of and with of and systemic The of clinical and on the rate of and of pericardial the of the pericardium and the and of the cardiac for cardiac are in of cardiac The of the pericardium as by pericardial is an by an a the final critical cardiac and the during the a patient with clinical of cardiac diagnostic tools are may of with and are to be an of the of pericardial and heart. is the most diagnostic to pericardial and its and of is to with and of can be by of the of the late of the in and in pulmonary in and and are available and are is not is to cardiac It of and of cardiac an on the and a on the of in the heart are in the of The treatment of cardiac of the pericardial by with the of or and should be without in is by a in as or in with into the A has been by the ESC on and Pericardial in order to the of the and the of the patient to a is on expert consensus and in order to be recommended in clinical practice. for the and treatment of cardiac of of recommendations. can after any pericardial disease process, but only The of is to the in and in and pericardial diseases and in A of patients with have been from and after The most in developed were or post-cardiac for disease or or in and in is only a of in developed it is a in developing However, this may be from and patients with is by of the to pericardial The clinical is by and of heart with and in the of or myocardial disease or and The between the pericardial and the of is and is a from to and may of the patient can be by a to myocardial or in and pericardial and in may also be with pericardial in to of the is in with and without pericardial A of is on the of and of heart and to pericardial by one or including and cardiac The is with for the of cardiac magnetic computed of of recommendations. a of for the from cardiac magnetic computed is a in on was as the ratio of the to the in diagnostic criteria for the of has been by the and or with either or ratio may to if all criteria are with a of to the of treatment of is medical may have a in at medical of may be to the to may the of from to medical on anti-inflammatory may the in of a as a during the of The of and evidence of pericardial by on and/or may be to patients with forms of where anti-inflammatory should be and may the for medical is and at of in and when is or at these medical should if this is because have a and a if is The of has been by forms of syndromes and treatment of the pericardial syndromes are in and of pericardial syndromes from A of with and and with anti-inflammatory The clinical the of acute with to which the process is in the of evidence that the condition is or pericardial patients with are may be given a trial of management for the pericardium is on and/or with and may be to pericardial The pericardial is in patients with the of pericardial is However, pericardial may be in this the pericardium not only the cardiac but can also pericardial to of cardiac is to be in developing with only published of in developed are the of pericardial disease in However, is the most in developing infection and and pericardial with have clinical of pericardial or or The of during in patients to have cardiac these it is recommended that heart and systemic arterial are during A after may also be to heart or However, may be for the of The layer of which is responsible for the of this process, is not to a that is on careful of of can be for cardiac and can also be in these without data may also be provided by The of in pericardial disease is well the not only to evaluate pericardial cardiac and but also for the of from of with magnetic resonance during an accurate evaluation of and it is the visceral layer of pericardium and not the parietal layer that the visceral must be However, the visceral of the is of an in is for should be only at with in for is the of treatment in patients with have and as or However, should be in patients with either or disease and in with myocardial or renal of the pericardium has a from to must be as as is and should be by to a with a interest in pericardial disease may be in with in this with or from and the is of end-stage disease a cardiac at to and/or to or is with a outcome, because it as well as pericardial of are renal pulmonary level and Pericardial impact on after in patients with Child–Pugh or was to be in patients with a and end-stage renal disease an of after this it appropriate to the for the of after in patients with for of cardiac magnetic C-reactive computed of of recommendations. can pericardial as a at the of the on the other in the heart and with to cardiac and the of pulmonary pulmonary and and is the in patients with pericardial because it pericardial and cardiac as well as to myocardial patients with acute may have a the of a pericardial is with acute and is one of the criteria for its may help to acute from myocardial by with in the of patients with acute However, of patients with acute and myocardial involvement may with provides the most way of pericardial and its The of pericardial on is by the of the between the epicardium and parietal order to it is recommended that the be and the in a way in the including not only the but also the of each However, the is to the of of the to its pericardial or pericardial that after cardiac may be to a and may in pericardial syndromes are in the should be as a to is the most accurate to and with to
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优美的豪英完成签到,获得积分10
刚刚
科研通AI65的应助被晚风采纳,获得10
8秒前
14秒前
15秒前
leo发布了新的文献求助10
19秒前
32秒前
风一样的风干肠完成签到 ,获得积分10
33秒前
37秒前
yqt完成签到,获得积分10
39秒前
39秒前
39秒前
40秒前
fantasy的应助被科研通管家采纳,获得10
40秒前
40秒前
40秒前
晚风发布了新的文献求助10
44秒前
48秒前
xin完成签到,获得积分10
52秒前
Owen的应助被leo采纳,获得10
53秒前
你奶奶完成签到,获得积分10
55秒前
丘比特的应助被你奶奶采纳,获得10
1分钟前
Owen的应助被诚心的茉莉采纳,获得10
1分钟前
orixero的应助被白华苍松采纳,获得10
1分钟前
1分钟前
仁爱的鹤轩完成签到,获得积分10
1分钟前
leo发布了新的文献求助10
1分钟前
小王快毕业完成签到,获得积分20
1分钟前
CodeCraft的应助被leo采纳,获得10
1分钟前
晚风发布了新的文献求助10
1分钟前
JY发布了新的文献求助10
1分钟前
1分钟前
今后的应助被林林采纳,获得10
1分钟前
机灵的以莲完成签到,获得积分10
1分钟前
yc发布了新的文献求助10
1分钟前
1分钟前
leo发布了新的文献求助10
1分钟前
wanci的应助被leo采纳,获得10
2分钟前
半山听雨N完成签到 ,获得积分10
2分钟前
LL发布了新的文献求助10
2分钟前
在水一方的应助被deng20065采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852047
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436240
关于科研通互助平台的介绍 2559964
邀请新用户注册赠送积分活动 2482824